Your cart is currently empty!
AlphaThera today announced its relocation to a significantly larger laboratory and office facility at 3675 Market Street in the heart of Philadelphia’s University City, marking an important milestone in the company’s growth.
The move will provide the company with twice the space of their existing location, combining both laboratory and office space to allow for further development of their renowned oYo-Link® Antibody Labeling Technology.
Over the past five years the biotech start-up has expanded the oYo-Link® portfolio to include a range of labels popular with biotechs and academic institutions across the US, Europe and further afield. Their highly regarded oYo-Link® Oligo conjugation technology has established a new benchmark in the field of spatial biology, while their Conjugation Service has proven especially attractive to customers seeking a cost-effective, high-quality solution to outsource antibody labelings.
More recently, AlphaThera partnered with Columbia Biosciences to introduce fluorescent proteins to the oYo-Link portfolio, with the two new oYo-Link® SureLight® fluorescent proteins scheduled for launch within the next couple of months.
The relocation allows for expansion of AlphaThera’s R&D and operations capabilities to enable continued product development, and to ensure the Company can continue to meet customer demand whilst maintaining their exceptionally high standards across both product and customer service.
Dr Andrew Tsourkas, Co-Founder of AlphaThera commented ‘The additional space will allow us to build on the success of oYo-Link with more facilities to expand our R&D capacity, while continuing to meet the needs of our growing customer base. The move not only expands our capacity but also places the team in a vibrant location with improved facilities and surroundings!’